Health Care • Biotechnology: Pharmaceutical Preparations
$29.73 ▼ -1.29
(-4.16%)
MKT CAP: $5.38B • VOL: 2.00M
52W L $14 52W H $44
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$25
MEDIAN
$33
MEAN
$34
HIGH
$40
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE COGT TAPE
COGT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $35.97 | $34.19 | 2025-02-14 | $27.05 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $37.46 | $35.08 | 2025-02-06 | $27.95 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $33.89 | $32.70 | 2025-01-29 | $28.54 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $30.32 | — | 2025-01-17 | $29.14 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $26.16 | $28.24 | 2025-01-09 | $26.46 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $35.38 | $30.92 | 2024-12-18 | $25.87 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $28.84 | $30.03 | 2024-12-04 | $27.65 | -4.3% | 48% | C |